United States Patent and Trademark Office

Syniti Announces Key Financial & Company Highlights for First Half 2023

Retrieved on: 
Tuesday, August 8, 2023
Knowledge, Data management, Patent, Senior, Imperial Brands, SAP, LS, Certification, SKP, United States Patent and Trademark Office, Singapore Airlines, Acquisition, ACV, CIO, Organization, Levi Strauss & Co., Video game, Management

BOSTON, Aug. 8, 2023 /PRNewswire/ -- Syniti, a global leader in enterprise data management, today announced key financial and company milestones for the second quarter and first half of 2023. The company sees its customers increasingly recognizing the importance of a "data-first" strategy as they embark on critical business transformation projects like integrating an acquisition, carving out a divestiture or moving to SAP S/4HANA®.

Key Points: 
  • BOSTON, Aug. 8, 2023 /PRNewswire/ -- Syniti, a global leader in enterprise data management, today announced key financial and company milestones for the second quarter and first half of 2023.
  • Twenty-two clients have adopted the company's new cloud-native Syniti Knowledge Platform (SKP), which is also resold by SAP as SAP® Advanced Data Migration & Management by Syniti, since becoming generally available in early 2023.
  • Services revenue grew by 5% in the first half of 2023 versus first half of 2022.
  • Syniti was listed for the tenth year in a row on the DBTA 100 : The Companies that Matter Most in Data for 2023.

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

Retrieved on: 
Tuesday, August 8, 2023
1836 U.S. Patent Office fire, Frontotemporal dementia, Patent, Single, Partnership, Central nervous system, Syndrome, Therapy, Bank statement, United States Patent and Trademark Office, Rett syndrome, Clinical trial, SIGMAR1, Partex, AND, Clinical Global Impression, Biomarker, Publication, Doctor of Philosophy, CNS, EDGAR, Trial of the century, Intellectual, Conference call, Alzheimer's disease, DSM-IV codes, American Journal, Patient, Webcast, Drug development, Disability studies, Research, Pharmacology, Conference, Treatment, Broadcasting, Pharmaceutical industry, Fine chemical, Video game, Schizophrenia

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2023.

Key Points: 
  • Company expects to announce topline results from this study in the second half of 2023.
  • Alzheimer’s disease: Full data ANAVEX®2-73-AD-004, including newly available preliminary results of surrogate biomarkers of pivotal Phase 2b/3 clinical trial.
  • General and administrative expenses for the quarter of $3.2 million compared to $3.2 million for the comparable quarter of fiscal 2022.
  • Research and development expenses for the quarter of $10.3 million compared to $9.3 million for the comparable quarter of fiscal 2022.

Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform

Retrieved on: 
Thursday, August 3, 2023
Patent, Aerosol spray dispenser, Gastrointestinal tract, Aviation, Therapy, United States Patent and Trademark Office, SAN, Delivery, Disease, Pharmaceutical industry

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.
  • 11,707,610 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract,” and has allowed U.S.
  • “These latest patents cover key features of our unique liquid jet injection technology, including its energy source, thereby broadening the scope of protection around our BioJet platform,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.
  • Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 11 issued patents and 27 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs.

Hopr.co Granted Second Patent for Secure Communications Technology

Retrieved on: 
Thursday, August 3, 2023
Online Privacy, Data Management, Security, Technology, Software, Networks, Patent, Communication, United States Patent and Trademark Office, TLS, Access control, US, AMTD, Synchronization, Risk, News, AWS, IEEE 802.1X, Television, Tourism

Hopr.co , a leader in securing workloads and data-in-transit everywhere in the cloud, announced today that it has been granted US Patent 11,716,312, “ Platform for Optimizing Secure Communications ,” by the United States Patent and Trademark Office (USPTO.)

Key Points: 
  • Hopr.co , a leader in securing workloads and data-in-transit everywhere in the cloud, announced today that it has been granted US Patent 11,716,312, “ Platform for Optimizing Secure Communications ,” by the United States Patent and Trademark Office (USPTO.)
  • The patent extends Hopr’s initial “Password Hopping System'' technology to cloud machines with a new and more sophisticated feature that addresses the increased cyber risk of legacy transport security by catering to the speed and scale of cloud operations.
  • The second patent also covers improvements that:
    “We are thrilled to unveil our improved ‘Password Hopping System’ technology, as well as announce receipt of Hopr’s second patent,” said Tom McNamara, Founder and CEO, Hopr.co.
  • This effort demonstrates not only the need for Hopr’s technology within the marketplace, but its ingenuity compared to other technologies and innovations.

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Central nervous system, Therapy, Tic disorder, Face, United States Patent and Trademark Office, DSM-IV codes, Tourette syndrome, Dystonia, FSE, IP, TEL, Disorder, Parkinson's disease, CWY, Chorea, Pharmaceutical industry, Dyskinesia

The provisional patent application was filed with the United States Patent and Trademark Office.

Key Points: 
  • The provisional patent application was filed with the United States Patent and Trademark Office.
  • This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.
  • This patent prospect corresponds well with SciSparc’s robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.
  • Our collaboration with Clearmind continues to bear fruit and emphasizes our commitment to pioneering innovative treatments for conditions with unmet need,” stated SciSparc’s Chief Executive Officer, Oz Adler.

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Obesity, Therapy, Face, United States Patent and Trademark Office, DSM-IV codes, MEAI, Dystonia, FSE, Disorder, Parkinson's disease, Patient, CWY, Myenteric plexus, Chorea, Pharmaceutical industry, Dyskinesia

The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.

Key Points: 
  • The patent application refers to the psychedelic molecule 3-Methylmethcathinone ("3-MMC”) as a potential treatment for Dyskinesia thus expanding Clearmind’s IP portfolio for innovative molecules, new indications and treatments.
  • "Clearmind continues to strengthen its position as a leader in the psychedelic-derived therapeutics industry through an aggressive strategy to expand our IP portfolio.
  • Clearmind has a broad IP footprint in the psychedelic space with 30 patents and patent applications across 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.
  • The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's Palmitoylethanolamide for treating alcohol use disorder, cocaine addiction, and obesity, as well as related metabolic disorders.

Itential Announces Issuance of Two New U.S. Patents for Its Network Integration, Automation, & Orchestration Technology

Retrieved on: 
Tuesday, August 1, 2023
1836 U.S. Patent Office fire, Patent, Software as a service, Freedom, United States Patent and Trademark Office, API, IP, Organization, Cisco, Entrepreneurship, Ecosystem, SASE, United States patent law, News, Automation, Information technology, Mobile phone

ATLANTA, Aug.1, 2023 /PRNewswire-PRWeb/ -- Itential, the leading cloud-based network automation and orchestration platform, announced today that the United States Patent and Trademark Office (USPTO) has issued two patents related to aspects of its API integration, data federation, and transformation capabilities for hybrid multi-cloud network automation. Today's news further solidifies Itential's leadership in driving innovation for a more integrated, programmable, network-first automation ecosystem.

Key Points: 
  • The Itential Automation Platform is built on a flexible, dynamic integration model for network automation.
  • Itential provides out-of-the-box, no-cost integrations to all network and IT systems so network teams can easily build end-to-end automations across their entire network infrastructure.
  • Itential's API federation capabilities enable users to leverage a single aggregated API for the entire network, simplifying automation across multiple network technologies.
  • "These patents are critical building blocks of our current portfolio capabilities and future product roadmap," said Chris Wade, Co-Founder and CTO of Itential.

Therapeutic Solutions International Prevention Subsidiary Campbell Neurosciences Receives Notice of Allowance on Suicide Prevention Drug Candidate

Retrieved on: 
Monday, July 31, 2023
Mental Health, Health, Other Health, General Health, Research, Science, Pharmaceutical, Patent, Suicide, United States Patent and Trademark Office, Immunity, TSOI, Brain, Patient, Risk, Diagnosis, Encephalitis, Neuroinflammation, Pharmaceutical industry

Therapeutic Solutions International, Inc. (TSOI), announced today issuance of a Notice of Allowance from the United States Patent and Trademark Office on its patent application covering a novel composition of matter being developed for prevention of suicide.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today issuance of a Notice of Allowance from the United States Patent and Trademark Office on its patent application covering a novel composition of matter being developed for prevention of suicide.
  • “Our findings, as well as those of independent researchers, strongly suggest a specific type of neuroinflammation contributes to suicidal thoughts and actions.
  • Importantly, these thoughts of self-harm cease when the drugs are discontinued,” said Thomas Ichim, Ph.D., President, and Chief Scientific Officer of Campbell Neurosciences.
  • “The speed at which Campbell Neurosciences is moving in meeting its milestones is truly inspiring,” stated Timothy Dixon, President, and CEO of Therapeutic Solutions International and Chairman of Campbell Neurosciences.

Shoals Technologies Group Files Motion to Amend Patent Infringement Complaint with ITC, Adding Additional Claims Against Voltage with New Technology Patent

Retrieved on: 
Thursday, July 27, 2023
U.S. Patent No. 1, Patent, EV, United States International Trade Commission, United States Patent and Trademark Office, Tariff Act, Voltage, Complaint, Shoal, Motion, District court, Engineering, ITC, BLA, Generic drug, Printed circuit board

On June 27, 2023, the United States Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • On June 27, 2023, the United States Patent and Trademark Office issued U.S. Patent No.
  • 11,689,153 B2 (the “’153 patent”), owned by Shoals and relating to improved connectors for solar panel arrays.
  • Upon issuance of the ‘153 patent’ Shoals filed a motion to amend its patent infringement complaint with the ITC, adding additional claims against Voltage.
  • As previously announced , the U.S. ITC has instituted an investigation into allegations of patent infringement against Hikam America, Inc. and Voltage, LLC.

Toyota's Collaborative Safety Research Center Expands Latest Phase of Research with New Projects

Retrieved on: 
Thursday, July 27, 2023
Patent, Happiness, United States Patent and Trademark Office, University, TMNA, Research, Toyota, Hospital, Engineering, CSRC, ADAS, Medical device

ANN ARBOR, Mich., July 27, 2023 /PRNewswire/ -- Toyota's Collaborative Safety Research Center (CSRC) today announced plans to launch three new projects as part of its next phase of research, dedicated to advancing safety in mobility technologies. The research projects include an investigation on driver support features for vehicle lane centering, the creation of an in-vehicle intervention prototype to promote safe driving and the use of data to help improve technology to aid driver decision making to encourage safer driving behavior. 

Key Points: 
  • Toyota created the Collaborative Safety Research Center (CSRC) in 2011 to advance mobility safety for industry and society through open collaborations with universities, hospitals and other institutions.
  • With current commitments, to date CSRC has received $115 million for foundational and applied safety research, including development of tools and testing procedures related to advanced driver assistance systems (ADAS) and research into human factors on vehicle safety, among others.
  • Safety Assurance: By investigating traffic environment, human drivers and potential safety hazards, CSRC aims to enhance safe operations and mitigate risks associated with mobility technologies.
  • Assessment: CSRC focuses on quantifying mobility safety measures to facilitate informed decision-making and drive effective safety strategies.